Recent 8-K filings for PBLS

• September 15, 2026, 4:15 PM ET other material materiality 0.50 neutral item 7.01

  Parabilis to present updated zolucatetide data in desmoid tumors at ESMO 2026

  Updated Phase 1/2 zolucatetide data in desmoid tumors to be presented at ESMO Congress 2026 in Madrid.

• September 2, 2026, 4:05 PM ET leadership materiality 0.50 neutral item 5.02

  Parabilis Medicines CMO Fawzi Benzaghou to depart effective Sept 30, 2026

  Chief Medical Officer Fawzi Benzaghou, M.D. and company mutually agreed to his transition, effective September 30, 2026.

• August 25, 2026, 4:10 PM ET leadership materiality 0.30 neutral item 5.02item 7.01item 9.01

  Parabilis Medicines appoints Craig Tendler to board as independent Class II director

  Board expanded to nine; Craig Tendler, M.D., appointed Class II director on Aug 22, 2026, term to 2028.

• August 13, 2026, 7:19 AM ET earnings materiality 0.85 positive item 2.02item 7.01item 9.01

  Parabilis Q2 net loss $52.5M; $1.1B cash after $770.5M IPO; Regeneron deal up to $2.2B

  Net loss $52.5M in Q2 2026 vs $34.8M prior year; R&D $39.4M, G&A $11.7M.

• June 11, 2026, 4:12 PM ET other material materiality 0.75 positive item 1.01item 3.02item 5.03item 9.01 ◈ Governance Changes ×2◈ Equity Issuances◈ Material Agreements

  Regeneron invests $75M in Parabilis at 10% discount to IPO price in concurrent private placement

  Purchased 4,166,666 shares at 90% of $20 IPO price ($18/share); total $75M.

Materiality & sentiment trend

Max materiality 0.85 · Median 0.50 · Most common event other_material

2 positive 0 negative 3 neutral

source · PBLS on sec.gov